Gathering the record
Relay is organizing the evidence and source boundaries.
Synthetic peptidyl growth hormone secretagogue
Hexarelin is a synthetic growth-hormone secretagogue that can strongly stimulate acute GH release in people. It also affects prolactin, ACTH, and cortisol, and repeated exposure can reduce the GH response. Human studies do not establish it for bodybuilding, recovery, fat loss, longevity, or sleep improvement.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
Hexarelin is an experimental peptide that activates a ghrelin-related signal and can strongly stimulate short-term growth-hormone release.
Researchers used it to study hormone physiology, repeated exposure, sleep, and acute heart function. The compound is especially informative because it also changes prolactin, stress-related hormones, and its own response over time.
Several small controlled studies consistently show acute growth-hormone release. Other human work found additional hormone changes, reduced response during repeated exposure, and less slow-wave sleep in a tiny overnight study rather than a simple sleep improvement.
Long-term benefit and safety, glucose effects, cardiovascular outcomes, repeated stress-hormone and prolactin effects, body composition, recovery, longevity, and commercial-product quality remain unresolved. Hexarelin is not approved.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
A small controlled human study compared several administration routes to measure acute growth-hormone release.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Controlled experiments characterize acute hormone release and route effects, but clinical-outcome research is absent.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Acute GH release is consistent; long-term benefit, safety, and sustained response are unresolved.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Only 12 healthy volunteers were included, and the study measured an acute hormone response. Different route conditions do not establish route equivalence, chronic benefit, a consumer schedule, or long-term safety. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
Multiple small controlled endocrine studies consistently demonstrate acute GH release and document prolactin, ACTH, and cortisol effects; a 16-week study showed progressive attenuation of the GH response.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Long-term clinical benefit and safety, including repeated HPA-axis and prolactin effects, glucose and metabolic consequences, cardiovascular risk, receptor desensitization, and the quality of unapproved commercial material.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
It belongs to the GHRP family and is mechanistically distinct from GHRH analogs such as Sermorelin or Tesamorelin and from direct somatropin replacement.
The effect was observed in small endocrine challenge studies across several protocol-specific routes and doses.
Several acute studies documented lactotroph and hypothalamo-pituitary-adrenal effects in addition to GH release.
This is evidence of desensitization or response attenuation, not evidence for a validated cycle design.
The direct sleep evidence does not support a simple claim that Hexarelin improves deep sleep.
Interesting acute physiology is not the same as fewer heart-failure events, improved survival, or durable functional benefit.
The human record is dominated by endocrine challenge studies and small acute cardiovascular experiments.
Historical study routes and doses describe research procedures and do not validate modern commercial research products.
Mechanisms
Hexarelin is a synthetic hexapeptide in the GHRP family that activates growth-hormone-secretagogue signaling at hypothalamic and pituitary sites. Small controlled human studies demonstrate robust acute GH release, but also prolactin and hypothalamo-pituitary-adrenal activation. Repeated administration produced response attenuation in a 16-week elderly cohort, and a nocturnal placebo-controlled study reported reduced slow-wave sleep measures despite higher GH. Specialized acute cardiac studies suggested short-lived GH-independent hemodynamic effects in selected monitored patients, but no long-term cardiovascular outcomes program was identified. The record does not establish anabolic, body-composition, recovery, longevity, or sleep benefit in healthy users.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Placebo-controlled overnight sleep EEG and hormone profiling
Seven healthy young volunteers
Hexarelin increased several hormones but reduced stage-4 sleep and total-night delta power in this small study.
Study administration: Four protocol-specific nocturnal hexarelin administrations or placebo
Limitations: A seven-person one-night study cannot establish chronic sleep effects, but it directly contradicts simple claims that hexarelin necessarily improves deep sleep.
Intensive 24-hour sampling after two or three subcutaneous administrations
Six healthy young men
Two and three administrations increased 24-hour GH secretion to a similar extent. IGF-1 did not change during the one-day schedules, and a later challenge showed a blunted GH response.
Study administration: Two or three protocol-specific subcutaneous hexarelin administrations
Limitations: One-day exposure in six men cannot establish sustained anabolic, recovery, body-composition, or safety outcomes.
Controlled comparison of hexarelin, CRH, desmopressin, and combinations
15 healthy young men
Hexarelin significantly stimulated ACTH and cortisol as well as GH and prolactin, supporting endocrine activity beyond selective GH release.
Study administration: Protocol-specific intravenous endocrine challenge tests
Limitations: Acute endocrine physiology does not quantify long-term risk or establish a therapeutic benefit.
Dose-response comparison with GHRH and low-dose combination testing
Healthy adult men
Hexarelin increased GH, prolactin, and cortisol in a dose-dependent pattern. Low-dose hexarelin combined with GHRH produced strong GH release with less cortisol effect in that experiment.
Study administration: Protocol-specific intravenous hexarelin and GHRH exposures
Limitations: Small acute endocrine study. Hormone peaks are not clinical outcome evidence and do not establish a safe chronic combination strategy.
Within-subject comparison of several administration routes and doses
12 healthy young volunteers
Hexarelin produced strong acute GH release after intravenous and subcutaneous administration, with smaller or variable responses through other studied routes.
Study administration: Protocol-specific intravenous, subcutaneous, intranasal, and oral hexarelin exposures; descriptive research context only
Limitations: Acute hormone release in 12 healthy volunteers does not establish long-term clinical benefit, body-composition change, recovery, muscle gain, safety, or consumer route equivalence.
Controlled intraoperative hemodynamic comparison
24 men with coronary artery disease undergoing bypass surgery
Hexarelin produced a short-lived increase in several cardiac-performance measures during surgery that was not shared by GHRH or recombinant GH.
Study administration: Single intravenous hexarelin, GHRH, recombinant GH, or placebo
Limitations: Specialized acute perioperative physiology cannot establish chronic heart-failure benefit, reduced events, improved survival, or safety outside monitored research settings.
Twice-daily subcutaneous administration with serial challenge testing
12 healthy elderly participants
The GH response progressively decreased during repeated treatment and returned toward baseline after a four-week washout.
Study administration: Historical twice-daily protocol-specific hexarelin administration
Limitations: Small historical study without long-term clinical outcomes. It demonstrates attenuation, not an optimal cycle or dosing schedule.
ClinicalTrials.gov term search
Population not stated.
Relay did not identify a modern registered Hexarelin development program establishing long-term recovery, muscle, body-composition, sleep, or cardiovascular outcomes.
Study administration: Not stated in the current record.
Limitations: A registry search cannot prove that no unregistered or non-U.S. study exists.
Safety snapshot
No source-qualified adverse-event pattern is represented in the current record.
Evidence boundaryHuman exposure is present, but the record is not detailed enough to characterize a reliable adverse-event pattern.
The current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryNot FDA approved; no approved Hexarelin product label or modern outcomes program identified Long-term clinical benefit and safety, including repeated HPA-axis and prolactin effects, glucose and metabolic consequences, cardiovascular risk, receptor desensitization, and the quality of unapproved commercial material.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-07-31
2026-07-31
2004-08-01 · PMID 15177700 · DOI 10.1016/S0306-4530(03)00152-5
2002-07-19 · PMID 12144941 · DOI 10.1016/S0014-2999(02)01934-9
2002-03-01 · PMID 11888836 · DOI 10.1530/eje.0.1460310
2002-03-01 · PMID 11959048 · DOI 10.1016/S1388-9842(01)00223-9
1999-01-01 · PMID 10404825
1998-01-01 · PMID 10990150
1996-12-01 · PMID 8954038 · DOI 10.1210/jcem.81.12.8954038
1994-03-01 · PMID 8126144 · DOI 10.1210/jcem.78.3.8126144